| 27/06 | Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver .. |  |
| 27/06 | ARBUTUS BIOPHARMA: Presents New Data on AB-729, AB-836 and AB-101 at the EASL Internation.. | |
| 27/06 | ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 27/06 | TRANSCRIPT: Arbutus Biopharma Corporation - Special Call | |
| 25/06 | Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver .. | |
| 25/06 | Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver .. | |
| 25/06 | Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EAS.. | |
| 09/06 | Arbutus to Present Seven Scientific Posters at EASL International Liver Congress 2022 | |
| 08/06 | CONFERENCE CALL & WEBCAST TO DISCUSS: 00 am ET - Form 8-K | |
| 08/06 | ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 08/06 | Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™.. | |
| 06/06 | Arbutus Biopharma, Vaccitech Dose First Patient in Trial Combining Therapies to Treat C.. | |
| 06/06 | ARBUTUS BIOPHARMA: Corporate Presentation - June 2022 | |
| 06/06 | ARBUTUS BIOPHARMA: and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining .. | |
| 06/06 | ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 06/06 | Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies.. | |
| 06/06 | Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies.. | |
| 06/06 | Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical.. | |
| 03/06 | ARBUTUS BIOPHARMA: Update on AB-729 and AB-836, an siRNA and capsid inhibitor currently i.. | |
| 02/06 | Arbutus to Participate in June Investor Conferences | |
| 02/06 | Arbutus to Participate in June Investor Conferences | |
| 31/05 | ARBUTUS BIOPHARMA CORP: Change in Directors or Principal Officers, Submission of Matters .. | |
| 26/05 | ARBUTUS BIOPHARMA: Announces Abstract Selected for Publication at the 2022 American Socie.. | |
| 26/05 | ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 26/05 | Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Cli.. | |
| 26/05 | Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Cli.. | |
| 24/05 | ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 17/05 | Arbutus to Present at H.C. Wainwright Global Investment Conference | |
| 05/05 | ARBUTUS BIOPHARMA CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND.. | |
| 05/05 | TRANSCRIPT: Arbutus Biopharma Corporation, Q1 2022 Earnings Call, May 05, 2022 | |
| 05/05 | ARBUTUS: Q1 Earnings Snapshot | |
| 05/05 | Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Reports Q1 Revenue $12.6M, vs. Stre.. | |
| 05/05 | ARBUTUS BIOPHARMA CORP: Results of Operations and Financial Condition, Other Events, Fina.. | |
| 05/05 | Arbutus Biopharma Corporation Reports Earnings Results for the First Quarter Ended Marc.. | |
| 05/05 | Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update | |
| 05/05 | Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update | |
| 21/04 | Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update | |
| 18/03 | Canadian Pfizer partner sues to head off patent lawsuit over COVID-19 vaccine | |
| 17/03 | Alnylam files patent infringement lawsuits against Pfizer, Moderna | |
| 11/03 | Moderna Has Standing To Appeal Because Of Risk Of Infringement Suit, But PTAB's Rejecti.. | |
| 03/03 | ARBUTUS BIOPHARMA CORP: Other Events, Financial Statements and Exhibits (form 8-K) | |
| 03/03 | ARBUTUS BIOPHARMA CORP Management's Discussion and Analysis of Financial Condition and.. | |
| 03/03 | ARBUTUS: Q4 Earnings Snapshot | |
| 03/03 | TRANSCRIPT: Arbutus Biopharma Corporation, Q4 2021 Earnings Call, Mar 03, 2022 | |
| 03/03 | ARBUTUS BIOPHARMA: Reports Fourth Quarter and Year End 2021 Financial Results and Provide.. | |
| 03/03 | ARBUTUS BIOPHARMA: Corporate Presentation - March 2022 | |
| 03/03 | ARBUTUS BIOPHARMA CORP: Results of Operations and Financial Condition, Other Events, Fina.. | |
| 03/03 | Arbutus Biopharma Corporation Reports Earnings Results for the Full Year Ended December.. | |
| 03/03 | Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corpora.. | |
| 03/03 | Arbutus Provides Pipeline Updates | |
| 03/03 | NORTH AMERICAN MORNING BRIEFING: Oil Prices Top -3- | |
| 03/03 | Timing Is Everything – Intervening Loss In Standing Results In Dismissal Of First.. | |
| 01/03 | What you need to know about the coronavirus right now | |
| 01/03 | Moderna Faces US Lawsuit From Arbutus For Allegedly Infringing Patents Used For COVID-1.. | |
| 28/02 | Health Care Down as Risk Aversion Weighs on Biotech -- Health Care Roundup | |
| 28/02 | Arbutus files patent infringement lawsuit against Moderna related to COVID shot | |
| 28/02 | Arbutus Biopharma, Genevant Sciences File Patent Infringement Lawsuit Against Moderna | |
| 28/02 | ARBUTUS BIOPHARMA CORP: Other Events (form 8-K) | |
| 28/02 | Arbutus files patent infringement lawsuit against Moderna | |
| 28/02 | Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Modern.. | |
| 28/02 | Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Modern.. | |
| 28/02 | ARBUTUS BIOPHARMA: Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers .. | |
| 17/02 | Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corpor.. | |
| 17/02 | Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corpor.. | |
| 24/01 | ARBUTUS BIOPHARMA: Corporate Presentation - January 2022 | |
| 24/01 | ARBUTUS BIOPHARMA: Announces 2022 Corporate Objectives and Provides Financial Update - Fo.. | |
| 24/01 | ARBUTUS BIOPHARMA CORP: Results of Operations and Financial Condition, Other Events, Fina.. | |
| 24/01 | Arbutus Announces 2022 Corporate Objectives and Provides Financial Update | |
| 24/01 | Arbutus Announces 2022 Corporate Objectives and Provides Financial Update | |
| 04/01 | Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference | |
| 2021 | Roivant Sciences Up 28%, Continuing Increase | |
| 2021 | MODERNATX, INC. V. ARBUTUS BIOPHARMA: Sublicense Not Enough To Show Standing | |
| 2021 | Patent Case Summaries | Week Ending December 3, 2021 | |
| 2021 | Arbutus, Antios Dose First Patient in Phase 2a Trial with AB-729, ATI-2173 for Hepatiti.. | |
| 2021 | ARBUTUS BIOPHARMA: Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed.. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Espańol
Franēais (France)
Nederlands (Nederland)
Nederlands (Belgiė)
Rapporto
